chronic myeloid leukemia (CML, granulocytic leukemia)

From Aaushi
Jump to navigation Jump to search

Etiology

  • acquired defect of clonal origin

Epidemiology

Pathology

Disease stages/progression:

Genetics

Clinical manifestations

Laboratory

Complications

Differential diagnosis

Management

Notes

More general terms

More specific terms

Additional terms

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 432-434
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 19. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2022
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  3. 3.0 3.1 Journal Watch 21(9):72, 2001 Druker BJ et al, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11287972
    Druker BJ et al, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11287973
    Goldman JM & Melo JV Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1084, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11287980
  4. 4.0 4.1 Journal Watch 22(7):53, 2002 Kantarjian H et al, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11870241
    Savage DG & Antman KH, Imatinib mesylate--a new oral targeted therapy. N Engl J Med 346:683, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11870247
  5. 5.0 5.1 5.2 Journal Watch 23(8):63-64, 2003 O'Brien SG et al, Imatinib compared with interferon and low-dose cytarabine for newly diagnoses chronic-phase chronic myeloid leukemia N Engl J Med 348:994, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12637609 Pegg K & Mackinnon S, Imatinib mesylate -- the new standard for treatment of chronic myeloid leukemia N Engl J Med 348:1048, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12637616
  6. Druker BJ et al, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:3408 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17151364
    Strebhardt K & Ullrich A. Another look at imatinib mesylate. N Engl J Med 2006, 355:2481 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17151370
  7. Geriatric Review Syllabus, 7th edition Parada JT et al (eds) American Geriatrics Society, 2010
    Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
  8. WHO Classification of Tumours. Tumors of Haematopoietic and Lymphoid Tissues. Jaffe et al. IARC Press 2001
  9. 9.0 9.1 Geriatrics at your Fingertips, 13th edition, 2011 Reuben DB et al (eds) American Geriatric Society
  10. 10.0 10.1 ARUP Consult: Chronic Myelogenous Leukemia - CML The Physician's Guide to Laboratory Test Selection & Interpretation https://www.arupconsult.com/content/chronic-myelogenous-leukemia
  11. FDA News Release: Dec. 14, 2012 FDA approves Iclusig to treat two rare types of leukemia http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm
    Cortes JE et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012 Nov 29; 367:2075. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23190221
  12. Le Gouill S, Talmant P, Milpied N, Daviet A et al Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol. 2000 Apr;18(7):1533-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10735902
  13. Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program. 2009:453-60. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20008231
  14. Marin D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol. 2010 Oct;47(4):312-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20875547
  15. Radich JP. The biology of chronic myelogenous leukemia progression: who, what, where, and why? Hematol Oncol Clin North Am. 2011 Oct;25(5):967-80, v. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22054729
  16. Kantarjian H, O'Brien S, Jabbour E et al Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 1;119(9):1981-7 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22228624
  17. 17.0 17.1 Prost S et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR-gamma agonists. Nature 2015 Sep 17; 525:380. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26331539
    Holyoake T and Vetrie D.Cancer: Repositioned to kill stem cells. Nature 2015 Sep 17; 525:328 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26331538
  18. 18.0 18.1 18.2 Fathi AT, Graubert TA, Kulkarni NM et al Case 37-2016 - An 86-Year-Old Woman with Leukocytosis and Splenomegaly. N Engl J Med 2016; 375:2273-2282. December 8, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27959687 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcpc1509539
  19. 19.0 19.1 Nelson R FDA Updates Labeling for Nilotinib: Treatment Can Be Stopped. Medscape - Dec 22, 2017. https://www.medscape.com/viewarticle/890566
  20. 20.0 20.1 O'Neil A. Evidence for New Method of Eradicating Residual CML Precursors. Targeting mitochondrial oxidative phosphorylation may help prevent CML relapse. MedPage Today. Jan 31, 2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/70855
  21. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012 Aug 16;120(7):1390-7. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22613793 Free PMC Article
  22. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 2018 Mar; 93:442 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29411417 Free article
  23. Chronic Myelogenous Leukemia (PDQ): Treatment http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional

Patient information

chronic myeloid leukemia patient information